Base de dados : MEDLINE
Pesquisa : D04.210.500.745.432.769.795.307 [Categoria DeCS]
Referências encontradas : 229 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 23 ir para página                         

  1 / 229 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28946122
[Au] Autor:Cho SH; Park JA; Zheng W; Abd El-Aty AM; Kim SK; Choi JM; Yi H; Cho SM; Afifi NA; Shim JH; Chang BJ; Kim JS; Shin HC
[Ad] Endereço:Department of Veterinary Pharmacology and Toxicology, College of Veterinary Medicine, Konkuk University, Seoul 143-701, Republic of Korea.
[Ti] Título:Quantification of bupivacaine hydrochloride and isoflupredone acetate residues in porcine muscle, beef, milk, egg, shrimp, flatfish, and eel using a simplified extraction method coupled with liquid chromatography-triple quadrupole tandem mass spectrometry.
[So] Source:J Chromatogr B Analyt Technol Biomed Life Sci;1065-1066:29-34, 2017 Oct 15.
[Is] ISSN:1873-376X
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:In this study, a simple analytical approach has been developed and validated for the determination of bupivacaine hydrochloride and isoflupredone acetate residues in porcine muscle, beef, milk, egg, shrimp, flatfish, and eel using liquid chromatography-tandem mass spectrometry (LC-MS/MS). A 0.1% solution of acetic acid in acetonitrile combined with n-hexane was used for deproteinization and defatting of all tested matrices and the target drugs were well separated on a Waters Xbridge™ C18 analytical column using a mobile phase consisting of 0.1% acetic acid (A) and 0.1% solution of acetic acid in methanol (B). The linearity estimated from six-point matrix-matched calibrations was good, with coefficients of determination ≥0.9873. The limits of quantification (LOQs) for bupivacaine hydrochloride and isoflupredone acetate were 1 and 2ngg , respectively. Recovery percentages in the ranges of 72.51-112.39% (bupivacaine hydrochloride) and 72.58-114.56% (isoflupredone acetate) were obtained from three different fortification concentrations with relative standard deviations (RSDs) of <15.14%. All samples for the experimental work and method application were collected from the local markets in Seoul, Republic of Korea, and none of them tested positive for the target drugs. In conclusion, a simple method using a 0.1% solution of acetic acid in acetonitrile and n-hexane followed by LC-MS/MS could effectively extract bupivacaine hydrochloride and isoflupredone acetate from porcine muscle, beef, milk, egg, shrimp, flatfish, and eel samples.
[Mh] Termos MeSH primário: Bupivacaína/análise
Resíduos de Drogas/análise
Fluprednisolona/análogos & derivados
Leite/química
Carne Vermelha/análise
Alimentos Marinhos/análise
[Mh] Termos MeSH secundário: Animais
Cromatografia Líquida/métodos
Enguias
Linguados
Fluprednisolona/análise
Modelos Lineares
Penaeidae
Reprodutibilidade dos Testes
Sensibilidade e Especificidade
Suínos
Espectrometria de Massas em Tandem/métodos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
55P9TUL75S (isoflupredone acetate); 9H05937G3X (Fluprednisolone); Y8335394RO (Bupivacaine)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171030
[Lr] Data última revisão:
171030
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170926
[St] Status:MEDLINE


  2 / 229 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27722767
[Au] Autor:Komori T; Honda T; Irie H; Otsuka A; Kabashima K
[Ad] Endereço:Department of Dermatology, Kyoto University Graduate School of Medicine, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan.
[Ti] Título:Lichen Planus in Irradiated Skin During Nivolumab Treatment.
[So] Source:Acta Derm Venereol;97(3):391-392, 2017 03 10.
[Is] ISSN:1651-2057
[Cp] País de publicação:Sweden
[La] Idioma:eng
[Mh] Termos MeSH primário: Anticorpos Monoclonais/efeitos adversos
Antineoplásicos/efeitos adversos
Neoplasias da Mama/patologia
Líquen Plano/induzido quimicamente
Neoplasias Hepáticas/tratamento farmacológico
Linfonodos/efeitos da radiação
Radiodermatite/induzido quimicamente
Pele/efeitos dos fármacos
Pele/efeitos da radiação
[Mh] Termos MeSH secundário: Administração Cutânea
Idoso
Biópsia
Feminino
Fluprednisolona/administração & dosagem
Fluprednisolona/análogos & derivados
Glucocorticoides/administração & dosagem
Seres Humanos
Líquen Plano/patologia
Neoplasias Hepáticas/secundário
Linfonodos/patologia
Metástase Linfática
Radiodermatite/patologia
Radioterapia/efeitos adversos
Indução de Remissão
Fatores de Risco
Pele/patologia
Resultado do Tratamento
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies, Monoclonal); 0 (Antineoplastic Agents); 0 (Glucocorticoids); 31YO63LBSN (nivolumab); 9H05937G3X (Fluprednisolone); S8A06QG2QE (difluprednate)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170505
[Lr] Data última revisão:
170505
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161011
[St] Status:MEDLINE
[do] DOI:10.2340/00015555-2545


  3 / 229 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27529841
[Au] Autor:Feiler DL; Srivastava SK; Pichi F; Bena J; Lowder CY
[Ad] Endereço:Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio.
[Ti] Título:RESOLUTION OF NONINFECTIOUS UVEITIC CYSTOID MACULAR EDEMA WITH TOPICAL DIFLUPREDNATE.
[So] Source:Retina;37(5):844-850, 2017 May.
[Is] ISSN:1539-2864
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: To evaluate the short-term safety and efficacy of topical difluprednate (0.05%) for the treatment of noninfectious uveitic cystoid macular edema. METHODS: Twenty-seven patients (35 eyes) undergoing treatment with difluprednate 4 times daily for 3 weeks for noninfectious uveitic cystoid macular edema were reviewed for visual acuity, intraocular pressure, optical coherence tomography, and fluorescein angiography results. A mixed model analysis was fit with each measure as the outcome, visit as the primary predictor, and patient and eye as random effects. RESULTS: Mean central foveal thickness decreased by 117 µm (P < 0.001) at 30 ± 15 days, 124 µm (P < 0.001) at 60 ± 15 days, and 152 µm (P < 0.001) at 180 ± 30 days. Complete resolution of intraretinal fluid was observed in 15 of 34 (44%) eyes at 30 ± 15 days, 11 of 21 (52%) eyes at 60 ± 15 days, and 9 of 12 (75%) eyes at 180 ± 30 days. Improvement in fluorescein leakage was noted in 7 of 8 eyes (88%). Visual acuity improved by a mean of 5 letters (P = 0.001) at 30 ± 15 days, 5.5 letters (P = 0.007) at 60 ± 15 days, and 7 letters (P = 0.032) at 180 ± 30 days. Mean increase in intraocular pressure was 1.48 mmHg at 30 ± 15 days (P = 0.080), 1.92 mmHg at 60 ± 15 days (P = 0.110), and 6.18 mmHg (P = 0.001) at 180 ± 30 days. CONCLUSION: Topical difluprednate is a well-tolerated and effective treatment for noninfectious uveitic cystoid macular edema with decreased central foveal thickness, mild improvement in visual acuity, and elevation of intraocular pressure observed in a few patients.
[Mh] Termos MeSH primário: Fluprednisolona/análogos & derivados
Glucocorticoides/administração & dosagem
Edema Macular/tratamento farmacológico
Uveíte/tratamento farmacológico
[Mh] Termos MeSH secundário: Administração Tópica
Adulto
Idoso
Feminino
Angiofluoresceinografia
Fluprednisolona/administração & dosagem
Seres Humanos
Pressão Intraocular
Masculino
Meia-Idade
Soluções Oftálmicas/administração & dosagem
Avaliação de Resultados (Cuidados de Saúde)/métodos
Estudos Retrospectivos
Tomografia de Coerência Óptica
Acuidade Visual
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Glucocorticoids); 0 (Ophthalmic Solutions); 9H05937G3X (Fluprednisolone); S8A06QG2QE (difluprednate)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171117
[Lr] Data última revisão:
171117
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160817
[St] Status:MEDLINE
[do] DOI:10.1097/IAE.0000000000001243


  4 / 229 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27177601
[Au] Autor:Ansai O; Shimomura Y; Fujimoto A; Sakai A; Tsuchida Y; Hayashi R; Shigehara Y; Hama N; Abe R
[Ad] Endereço:Division of Dermatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
[Ti] Título:Case of pemphigus herpetiformis with immunoglobulin G autoantibodies against desmocollin-3.
[So] Source:J Dermatol;44(1):104-105, 2017 Jan.
[Is] ISSN:1346-8138
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Autoanticorpos/sangue
Dermatite Herpetiforme/imunologia
Desmocolinas/imunologia
Imunoglobulina G/imunologia
Pênfigo/imunologia
[Mh] Termos MeSH secundário: Administração Cutânea
Administração Oral
Autoantígenos/imunologia
Biópsia
Dapsona/administração & dosagem
Dapsona/uso terapêutico
Dermatite Herpetiforme/sangue
Dermatite Herpetiforme/tratamento farmacológico
Dermatite Herpetiforme/patologia
Fármacos Dermatológicos/administração & dosagem
Fármacos Dermatológicos/uso terapêutico
Desmogleína 1/imunologia
Desmogleína 3/imunologia
Ensaio de Imunoadsorção Enzimática
Feminino
Imunofluorescência
Fluprednisolona/administração & dosagem
Fluprednisolona/análogos & derivados
Fluprednisolona/uso terapêutico
Glucocorticoides/administração & dosagem
Glucocorticoides/uso terapêutico
Seres Humanos
Meia-Idade
Colágenos não Fibrilares/imunologia
Pênfigo/sangue
Pênfigo/tratamento farmacológico
Pênfigo/patologia
Prurido/etiologia
Tomografia Computadorizada por Raios X
[Pt] Tipo de publicação:CASE REPORTS; LETTER
[Nm] Nome de substância:
0 (Autoantibodies); 0 (Autoantigens); 0 (DSC3 protein, human); 0 (DSG1 protein, human); 0 (DSG3 protein, human); 0 (Dermatologic Agents); 0 (Desmocollins); 0 (Desmoglein 1); 0 (Desmoglein 3); 0 (Glucocorticoids); 0 (Immunoglobulin G); 0 (Non-Fibrillar Collagens); 0 (collagen type XVII); 8W5C518302 (Dapsone); 9H05937G3X (Fluprednisolone); S8A06QG2QE (difluprednate)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170717
[Lr] Data última revisão:
170717
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160515
[St] Status:MEDLINE
[do] DOI:10.1111/1346-8138.13451


  5 / 229 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:27582676
[Au] Autor:Lu S; Taban M
[Ad] Endereço:Macula Retina Vitreous Center, Torrance, California.
[Ti] Título:Topical difluprednate for treatment of serous retinal detachment and panuveitis associated with Vogt-Koyanagi-Harada disease.
[So] Source:Digit J Ophthalmol;22(2):54-7, 2016.
[Is] ISSN:1542-8958
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Patients with bilateral serous retinal detachments and panuveitis related to Vogt-Koyanagi-Harada disease are commonly managed with oral corticosteroids, immunosuppressive agents, and/or intravitreal injections. We present the case of a 56-year-old Hispanic man with Harada disease whose bilateral serous retinal detachments and panuveitis were treated with topical corticosteroid difluprednate alone. Functional and anatomical recoveries were assessed by fluorescein angiograms and optical coherence tomography studies over a period of 9 months. The patient's serous retinal detachments resolved, and his vision and panuveitis improved dramatically over a period of 2 weeks, after which he was placed on a drop taper and maintenance therapy for the remainder of the 9 months.
[Mh] Termos MeSH primário: Fluprednisolona/análogos & derivados
Pan-Uveíte/tratamento farmacológico
Descolamento Retiniano/tratamento farmacológico
Síndrome Uveomeningoencefálica/complicações
[Mh] Termos MeSH secundário: Angiofluoresceinografia
Fluprednisolona/administração & dosagem
Fundo de Olho
Glucocorticoides/administração & dosagem
Seres Humanos
Injeções Intravítreas
Masculino
Meia-Idade
Soluções Oftálmicas
Pan-Uveíte/diagnóstico
Pan-Uveíte/etiologia
Descolamento Retiniano/diagnóstico
Descolamento Retiniano/etiologia
Tomografia de Coerência Óptica
Síndrome Uveomeningoencefálica/diagnóstico
Acuidade Visual
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Glucocorticoids); 0 (Ophthalmic Solutions); 9H05937G3X (Fluprednisolone); S8A06QG2QE (difluprednate)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170328
[Lr] Data última revisão:
170328
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160902
[St] Status:MEDLINE
[do] DOI:10.5693/djo.02.2015.05.004


  6 / 229 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27367745
[Au] Autor:Wilson ME; O'Halloran H; VanderVeen D; Roarty J; Plager DA; Markwardt K; Gedif K; Lambert SR
[Ad] Endereço:Storm Eye Institute, Medical University of South Carolina, Charleston, SC, USA.
[Ti] Título:Difluprednate versus prednisolone acetate for inflammation following cataract surgery in pediatric patients: a randomized safety and efficacy study.
[So] Source:Eye (Lond);30(9):1187-94, 2016 Sep.
[Is] ISSN:1476-5454
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:PurposeTo evaluate safety and efficacy of difluprednate 0.05% ophthalmic emulsion for treatment of postoperative inflammation after cataract surgery in pediatric patients.MethodsThis was a phase 3B, multicentre, randomized, double-masked, active-controlled study of patients aged 0-3 years who underwent uncomplicated cataract surgery in one eye, with/without intraocular lens implantation. Patients were randomized to receive difluprednate 0.05% four times daily or prednisolone acetate 1% for 14 days post surgery, followed by tapering for 14 days. Safety included evaluation of adverse events. Primary efficacy was the proportion of patients with an anterior cell grade of 0 (no cells) at day 14; secondary efficacy was a global inflammation score.ResultsForty patients were randomized to each treatment group. Adverse drug reactions included corneal oedema (difluprednate 0.5%, n=1; prednisolone acetate 1%, n=0) and increased intraocular pressure or ocular hypertension (n=2/group). Mean intraocular pressure values during treatment were 2-3 mm Hg higher with difluprednate 0.05% compared with prednisolone acetate 1%; mean values were similar between groups by the first week after treatment cessation. At 2 weeks post surgery, the incidence of complete clearing of anterior chamber cells was similar between groups (difluprednate 0.05%, n=30 (78.9%); prednisolone acetate 1%, n=31 (77.5%). Compared with prednisolone acetate 1%, approximately twice as many difluprednate 0.05%-treated patients had a global inflammation assessment score indicating no inflammation on day 1 (n=12 (30.8%) vs n=7 (17.5%) and day 8 (n=18 (48.7%) vs n=10 (25.0%).ConclusionsDifluprednate 0.05% four times daily showed safety and efficacy profiles similar to prednisolone acetate 1% four times daily in children 0-3 years undergoing cataract surgery.
[Mh] Termos MeSH primário: Extração de Catarata/efeitos adversos
Fluprednisolona/análogos & derivados
Glucocorticoides/uso terapêutico
Inflamação/tratamento farmacológico
Prednisolona/análogos & derivados
Uveíte Anterior/tratamento farmacológico
[Mh] Termos MeSH secundário: Administração Tópica
Afacia Pós-Catarata/etiologia
Afacia Pós-Catarata/cirurgia
Catarata/congênito
Pré-Escolar
Método Duplo-Cego
Feminino
Fluprednisolona/efeitos adversos
Fluprednisolona/uso terapêutico
Glucocorticoides/efeitos adversos
Seres Humanos
Lactente
Recém-Nascido
Inflamação/etiologia
Pressão Intraocular/efeitos dos fármacos
Implante de Lente Intraocular
Masculino
Soluções Oftálmicas
Prednisolona/efeitos adversos
Prednisolona/uso terapêutico
Uveíte Anterior/etiologia
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE III; COMPARATIVE STUDY; JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Glucocorticoids); 0 (Ophthalmic Solutions); 8B2807733D (prednisolone acetate); 9H05937G3X (Fluprednisolone); 9PHQ9Y1OLM (Prednisolone); S8A06QG2QE (difluprednate)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160702
[St] Status:MEDLINE
[do] DOI:10.1038/eye.2016.132


  7 / 229 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26874159
[Au] Autor:Symes RJ; Forooghian F
[Ad] Endereço:Department of Ophthalmology, University of British Columbia, Vancouver, BC.
[Ti] Título:Topical difluprednate monotherapy for uveitic macular edema.
[So] Source:Can J Ophthalmol;51(1):47-9, 2016 Feb.
[Is] ISSN:1715-3360
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To describe the use of topical difluprednate for the treatment of uveitic macular edema. DESIGN: Retrospective review of 3 consecutive cases of uveitic macular edema. METHODS: Patients were treated with topical difluprednate monotherapy. RESULTS: All patients experienced complete resolution of uveitic macular edema within 2-4 weeks. We observed a statistically significant improvement in central subfield macular thickness (p = 0.04). There was an overall improvement in visual acuity, but this result was not statistically significant (p = 0.33). CONCLUSIONS: Topical difluprednate can be effective for uveitic macular edema. Further investigation of this therapy in prospective randomized controlled trials is warranted.
[Mh] Termos MeSH primário: Fluprednisolona/análogos & derivados
Glucocorticoides/uso terapêutico
Edema Macular/tratamento farmacológico
Uveíte Anterior/tratamento farmacológico
Uveíte Intermediária/tratamento farmacológico
[Mh] Termos MeSH secundário: Administração Tópica
Adulto
Feminino
Fluprednisolona/uso terapêutico
Seres Humanos
Edema Macular/diagnóstico
Edema Macular/fisiopatologia
Masculino
Soluções Oftálmicas
Estudos Retrospectivos
Tomografia de Coerência Óptica
Uveíte Anterior/diagnóstico
Uveíte Anterior/fisiopatologia
Uveíte Intermediária/diagnóstico
Uveíte Intermediária/fisiopatologia
Acuidade Visual/efeitos dos fármacos
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Glucocorticoids); 0 (Ophthalmic Solutions); 9H05937G3X (Fluprednisolone); S8A06QG2QE (difluprednate)
[Em] Mês de entrada:1609
[Cu] Atualização por classe:161013
[Lr] Data última revisão:
161013
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160214
[St] Status:MEDLINE


  8 / 229 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:26855269
[Au] Autor:Borrás T; Buie LK; Spiga MG
[Ad] Endereço:Department of Ophthalmology, University of North Carolina School of Medicine, Chapel Hill, NC, USA.
[Ti] Título:Inducible scAAV2.GRE.MMP1 lowers IOP long-term in a large animal model for steroid-induced glaucoma gene therapy.
[So] Source:Gene Ther;23(5):438-49, 2016 05.
[Is] ISSN:1476-5462
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Current treatment of glaucoma relies on administration of daily drops or eye surgery. A gene therapy approach to treat steroid-induced glaucoma would bring a resolution to millions of people worldwide who depend on glucocorticoid therapy for a myriad of inflammatory disorders. Previously, we had characterized a short-term Adh.GRE.MMP1 gene vector for the production of steroid-induced MMP1 in the trabecular meshwork and tested reduction of elevated intraocular pressure (IOP) in a sheep model. Here we conducted a trial transferring the same transgene cassette to a clinically safe vector (scAAV2), and extended the therapeutic outcome to longer periods of times. No evidence of ocular and/or systemic toxicity was observed. Viral genome distributions showed potential reinducible vector DNAs in the trabecular meshwork (0.4 v.g. per cell) and negligible copies in six major internal organs (0.00002-0.005 v.g. per cell). Histological sections confirmed successful transduction of scAAV2.GFP to the trabecular meshwork. Optimization of the sheep steroid-induced hypertensive model revealed that topical ophthalmic drug difluprednate 0.05% (durezol) induced the highest IOP elevation in the shortest time. This is the first efficacy/toxicity study of a feasible gene therapy treatment of steroid-induced hypertension using clinically accepted self-complementary adeno-associated vectors (scAAV) vectors in a large animal model.
[Mh] Termos MeSH primário: Terapia Genética
Glaucoma/terapia
Glucocorticoides/genética
Malha Trabecular/efeitos dos fármacos
[Mh] Termos MeSH secundário: Animais
Dependovirus/genética
Modelos Animais de Doenças
Fluprednisolona/administração & dosagem
Fluprednisolona/análogos & derivados
Vetores Genéticos
Glaucoma/genética
Glucocorticoides/uso terapêutico
Seres Humanos
Pressão Intraocular/efeitos dos fármacos
Metaloproteinase 1 da Matriz/genética
Metaloproteinase 1 da Matriz/uso terapêutico
Ovinos
Malha Trabecular/patologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Glucocorticoids); 9H05937G3X (Fluprednisolone); EC 3.4.24.7 (MMP1 protein, human); EC 3.4.24.7 (Matrix Metalloproteinase 1); S8A06QG2QE (difluprednate)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:170206
[Lr] Data última revisão:
170206
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160209
[St] Status:MEDLINE
[do] DOI:10.1038/gt.2016.14


  9 / 229 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26692064
[Au] Autor:Abu Samra K; Valdes-Navarro M; Lee S; Swan R; Foster CS; Anesi SD
[Ad] Endereço:Massachusetts Eye Research and Surgery Institution, Waltham, MA - USA.
[Ti] Título:A case of bilateral uveitis and papillitis in a patient treated with pembrolizumab.
[So] Source:Eur J Ophthalmol;26(3):e46-8, 2016 Apr 12.
[Is] ISSN:1724-6016
[Cp] País de publicação:Italy
[La] Idioma:eng
[Ab] Resumo:PURPOSE: Drug-induced uveitis is a well-known effect of ocular inflammation that has been reported with many medications. Pembrolizumab is a newer generation of the anti-programmed cell death-1 monoclonal antibodies that was recently approved by the Food and Drug Administration for the treatment of advanced melanoma. Immune-mediated adverse events involving different organs have been reported in recent literature in association with this drug. We present the first reported case of uveitis in association with pembrolizumab therapy. CASE REPORT: An 82-year-old man with stage IV melanoma was started on pembrolizumab infusion treatment every 3 weeks. Two months after initiating therapy, he presented with bilateral severe anterior uveitis and papillitis with fast and complete recovery after withholding further pembrolizumab infusions and treatment with topical steroid. Uveitis recurred after restarting pembrolizumab therapy. CONCLUSIONS: In current clinical practice, many new drugs are being approved, requiring better characterization of the prevalence, onset, and nature of adverse events in order to aid development of effective management strategies. Ophthalmologists should keep in mind that drugs are always a possible cause of ocular inflammation in patients presenting with uveitis.
[Mh] Termos MeSH primário: Anticorpos Monoclonais Humanizados/efeitos adversos
Antineoplásicos/efeitos adversos
Papiledema/induzido quimicamente
Uveíte Anterior/induzido quimicamente
[Mh] Termos MeSH secundário: Idoso de 80 Anos ou mais
Fluprednisolona/análogos & derivados
Fluprednisolona/uso terapêutico
Glucocorticoides/uso terapêutico
Seres Humanos
Infusões Intravenosas
Masculino
Melanoma/tratamento farmacológico
Melanoma/patologia
Recidiva Local de Neoplasia/induzido quimicamente
Recidiva Local de Neoplasia/tratamento farmacológico
Estadiamento de Neoplasias
Papiledema/diagnóstico
Papiledema/tratamento farmacológico
Neoplasias Cutâneas/tratamento farmacológico
Neoplasias Cutâneas/patologia
Uveíte Anterior/diagnóstico
Uveíte Anterior/tratamento farmacológico
Acuidade Visual
Campos Visuais
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies, Monoclonal, Humanized); 0 (Antineoplastic Agents); 0 (Glucocorticoids); 9H05937G3X (Fluprednisolone); DPT0O3T46P (pembrolizumab); S8A06QG2QE (difluprednate)
[Em] Mês de entrada:1609
[Cu] Atualização por classe:160416
[Lr] Data última revisão:
160416
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151223
[St] Status:MEDLINE


  10 / 229 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26333097
[Au] Autor:Knych HK; Harrison LM; White A; McKemie DS
[Ad] Endereço:K.L. Maddy Equine Analytical Chemistry Laboratory, School of Veterinary Medicine, University of California, Davis, 95616, CA, USA.
[Ti] Título:Disposition of isoflupredone acetate in plasma, urine and synovial fluid following intra-articular administration to exercised Thoroughbred horses.
[So] Source:Drug Test Anal;8(1):141-7, 2016 Jan.
[Is] ISSN:1942-7611
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:The use of isoflupredone acetate in performance horses and the scarcity of published pharmacokinetic data necessitate further study. The objective of the current study was to describe the plasma pharmacokinetics of isoflupredone acetate as well as time-related urine and synovial fluid concentrations following intra-articular administration to horses. Twelve racing-fit adult Thoroughbred horses received a single intra-articular administration (8 mg) of isoflupredone acetate into the right antebrachiocarpal joint. Blood, urine and synovial fluid samples were collected prior to and at various times up to 28 days post drug administration. All samples were analyzed using liquid chromatography-Mass Spectrometry. Plasma data were analyzed using a population pharmacokinetic compartmental model. Maximum measured plasma isoflupredone concentrations were 1.76 ± 0.526 ng/mL at 4.0 ± 1.31 h and 1.63 ± 0.243 ng/mL at 4.75 ± 0.5 h, respectively, for horses that had synovial fluid collected and for those that did not. The plasma beta half-life was 24.2 h. Isoflupredone concentrations were below the limit of detection in all horses by 48 h and 7 days in plasma and urine, respectively. Isoflupredone was detected in the right antebrachiocarpal and middle carpal joints for 8.38 ± 5.21 and 2.38 ± 0.52 days, respectively. Results of this study provide information that can be used to regulate the use of intra-articular isoflupredone in the horse.
[Mh] Termos MeSH primário: Fluprednisolona/análogos & derivados
Glucocorticoides/sangue
Glucocorticoides/urina
Cavalos/sangue
Cavalos/urina
[Mh] Termos MeSH secundário: Animais
Cromatografia Líquida/métodos
Feminino
Fluprednisolona/análise
Fluprednisolona/sangue
Fluprednisolona/farmacocinética
Fluprednisolona/urina
Glucocorticoides/análise
Glucocorticoides/farmacocinética
Cavalos/metabolismo
Masculino
Detecção do Abuso de Substâncias/métodos
Líquido Sinovial/metabolismo
Espectrometria de Massas em Tandem/métodos
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Glucocorticoids); 55P9TUL75S (isoflupredone acetate); 9H05937G3X (Fluprednisolone)
[Em] Mês de entrada:1610
[Cu] Atualização por classe:161230
[Lr] Data última revisão:
161230
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150903
[St] Status:MEDLINE
[do] DOI:10.1002/dta.1834



página 1 de 23 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde